Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023
Some items listed as REQUIRING PRE-AUTHORISATION:
- Forxiga (Dapagliflozin)
- Byetta (Exenatide)
- Janumet (Metformin/Sitagliptin)
- Onglyza (Saxagliptin)
- Januvia (Sitagliptin)
- Galvus (Vildagliptin) + including Metformin combinations
- Liptruzet (Atorvastatin/Ezetimibe)
- Ezetrol (Ezetimibe)
- Inegy(Ezetimibe/Simvastatin)
Details regarding the EXCLUDED ITEMS:
- Trulicity (Dulaglutide)
- Jardiance (Empagliflozin)
- Xultophy (Insulin Degludec and Liraglutide)
- Soliqua (Insulin Glargine and Lixisenatide)
- Victoza (Liraglutide)
- Synjardy (Metformin and Empagliflozin)
- Ozempic (Semaglutide)
Recent Posts
Advancing Kidney Transplant Transparency Through Patient Involvement
Enhancing Kidney Transplant Transparency
In a
AI in South African Healthcare: Professionals’ Confidence in Reducing Admissions and Enhanc...
AI Optimism in South Africa's Healthcare Landscape
AI in South African Healthcare is gaining momentum, as evidenced by the Philips Future Health Index (FHI...
Shifting Toward Sustainable Reimbursement Models in South Africa’s Healthcare Sector
Escaping Fee-for-Service: Pathways to Sustainable Reimbursement Models
The Council for Medical Schemes (CMS) Annual Report 2024/25 undersc...